Viatris Inc

Change company Symbol lookup

Select an option...

VTRS Viatris Inc

JGGC Jaguar Global Growth Corporation I

WHG Westwood Holdings Group Inc

BNOX Bionomics Ltd

PSO Pearson PLC

ERNA Eterna Therapeutics Inc

INDP Indaptus Therapeutics Inc

TSLX Sixth Street Specialty Lending Inc

WAVD Wavedancer Inc

SGBX Safe & Green Holdings Corp

Go

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils. (Zacks)

Viatris Inc. (VTRS) and Ocuphire Pharma Inc. (OCUP) said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye...(MarketWatch)

RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 Viatris Inc. (NASDAQ: VTRS), a global healthcare company, andOcuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on...(PR Newswire)

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to TIME's World's Best Companies 2023 list. This recognition of companies changing the world is presented by TIME, the 99-year-old global media brandand...(PR Newswire)

Nominations recognize innovative development of AVERSA™ abuse-deterrent transdermal technology ORLANDO, FL / ACCESSWIRE / September 12, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical...(Accesswire)

Smart Beta ETF report for RSPH(Zacks)

Wilmington, Delaware--(Newsfile Corp. - September 7, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Viatris Inc. (NASDAQ: VTRS) on behalf of stockholders.(Newsfile)

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.(Zacks)

Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.(Zacks)

Tentative approval will help enhance access to WHO-recommended paediatric regimen with the goal of improved adherence of HIV treatment for children in low- and middle-income countries Viatris Inc.(NASDAQ: VTRS),a global healthcare company, today...(PR Newswire)

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?(Zacks)

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viatris Inc. (NASDAQ: VTRS) on behalf of long-term stockholders following a class action complaint that was filed against...(BusinessWire)

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.(Zacks)

Companies in The News Are: KKR,SAGE,VTRS,FRPT(Zacks)

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.(Zacks)

Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance. (Zacks)

Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?(Zacks)

-- Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free Cash Flow of $447 Million for the Quarter (PR Newswire)

FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris' long-standing and continued commitment toward addressing the unmet...(PR Newswire)